Patents by Inventor Dario Braga

Dario Braga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220127283
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20220119410
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20220119403
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Publication number: 20200339600
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20200339599
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20200277301
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Patent number: 10703763
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: July 7, 2020
    Assignee: ALFASIGMA S.P.A.
    Inventors: Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga
  • Publication number: 20200002350
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 2, 2020
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Publication number: 20190263830
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20190263829
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20190135831
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: June 7, 2018
    Publication date: May 9, 2019
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20190135830
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin a and rifaximin 3, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: June 7, 2018
    Publication date: May 9, 2019
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20180291032
    Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 11, 2018
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria BARBANTI, Dario BRAGA
  • Publication number: 20180065987
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin cc and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 8, 2018
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20180065988
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 8, 2018
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20170275264
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 28, 2017
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Haiyang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
  • Publication number: 20170210757
    Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
    Type: Application
    Filed: September 1, 2016
    Publication date: July 27, 2017
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20170210758
    Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
    Type: Application
    Filed: September 2, 2016
    Publication date: July 27, 2017
    Inventors: Giuseppe Claudio VISCOMI, Manuela CAMPANA, Dario BRAGA, Donatella CONFORTINI, Vincenzo CANNATA, Paolo RIGHI, Goffredo ROSINI, Denis SEVERINI
  • Publication number: 20170189385
    Abstract: The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution.
    Type: Application
    Filed: August 11, 2016
    Publication date: July 6, 2017
    Inventors: Giuseppe Claudio VISCOMI, Laura CHELAZZI, Fabrizia GREPIONI, Dario BRAGA, Maddalena KINDT
  • Patent number: 9624192
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 18, 2017
    Assignee: Novartis AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang